BREAST CANCER PANEL 3

ER & PR receptor assays are routinely performed on Breast carcinomas to assess responsiveness to endocrine therapy and prognosis. Her-2/neu expression shows responsiveness to Herceptin therapy.

  • Test Type:
  • Pre-test Information:
    No special preparation required
  • Report Delivery:
    Sample Daily by 6 pm Report 5 days: Blocks / Sections / Smears 7 days: Tissue
  • Components:
    0

Sample Report